https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-09-19 / J. Dermatol. Sci. 2009 Jan;53(1):40-7
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-09-19 / J. Dermatol. Sci. 2009 Jan;53(1):40-72008-09-19 00:00:002019-02-15 09:19:14Immunohistological analysis of peptide-induced delayed-type hypersensitivity in advanced melanoma patients treated with melanoma antigen-pulsed mature monocyte-derived dendritic cell vaccination
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-09-01 / Expert Rev Vaccines 2008 Sep;7(7):937-49
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-09-01 / Expert Rev Vaccines 2008 Sep;7(7):937-492008-09-01 00:00:002019-02-15 09:19:22Melanoma vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-08-22 / Cancer Immunol. Immunother. 2009 Jan;58(1):1-14
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-08-22 / Cancer Immunol. Immunother. 2009 Jan;58(1):1-142008-08-22 00:00:002019-02-15 09:19:19Review of clinical studies on dendritic cell-based vaccination of patients with malignant melanoma: assessment of correlation between clinical response and vaccine parameters
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-08-01 / G Ital Dermatol Venereol 2008 Aug;143(4):235-50
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-08-01 / G Ital Dermatol Venereol 2008 Aug;143(4):235-502008-08-01 00:00:002019-02-15 08:49:31Dendritic cell vaccines in metastasized malignant melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-11 / Cancer Immunol. Immunother. 2009 Mar;58(3):361-71
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-11 / Cancer Immunol. Immunother. 2009 Mar;58(3):361-712008-07-11 00:00:002008-07-11 00:00:00TIMP-1-GPI in combination with hyperthermic treatment of melanoma increases sensitivity to FAS-mediated apoptosis
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-51
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Cancer Immunol. Immunother. 2008 Jul;57(7):1039-512008-07-01 00:00:002019-02-15 09:19:24Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-41
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Clin. Oncol. 2008 Jul;26(19):3235-412008-07-01 00:00:002019-02-15 09:19:25Phenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factor
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):555-62
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):555-622008-07-01 00:00:002019-02-15 09:19:26IFN-producing killer dendritic cells contribute to the inhibitory effect of poly I:C on the progression of murine melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-8
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / J. Immunother. 2008 Jul-Aug;31(6):591-82008-07-01 00:00:002019-02-15 09:19:26Phase Ib trial assessing autologous, tumor-pulsed dendritic cells as a vaccine administered with or without IL-2 in patients with metastatic melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2008-07-01 / Int J Immunopathol Pharmacol 2008 Jul-Sep;21(3):493-500
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2008-07-01 / Int J Immunopathol Pharmacol 2008 Jul-Sep;21(3):493-5002008-07-01 00:00:002019-02-15 09:19:20Strategies to overcome obstacles to successful immunotherapy of melanoma
